Discovery of Bishomo(hetero)arylpiperazines as Novel Multifunctional Ligands Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors
- 19 May 2010
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 53 (12) , 4803-4807
Abstract
As a continuation of our efforts to develop innovative ligands for D3, 5-HT1A, and 5-HT2A receptors with low propensity to block hERG channels, we propose a series bishetero(homo)arylpiperazines 5a−m as novel and potent multifunctional ligands characterized by low occupancy at D2 and 5-HT2C receptors.Keywords
This publication has 16 references indexed in Scilit:
- SchizophreniaThe Lancet, 2009
- Designed Multiple Ligands. An Emerging Drug Discovery ParadigmJournal of Medicinal Chemistry, 2005
- Novel antipsychotic agents: recent advances in the drug treatment of schizophreniaExpert Opinion on Therapeutic Patents, 2003
- Aripiprazole: Efficacy and tolerability profile of a novel-acting atypical antipsychoticDrugs of Today, 2003
- Olanzapine‐Associated Diabetes MellitusPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002
- AripiprazoleCNS Drugs, 2002
- Pyrrolo[1,3]benzothiazepine-Based Atypical Antipsychotic Agents. Synthesis, Structure−Activity Relationship, Molecular Modeling, and Biological StudiesJournal of Medicinal Chemistry, 2001
- Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysisBMJ, 2000
- New Antipsychotic Agents with Serotonin and Dopamine Antagonist Properties Based on a Pyrrolo[2,1-b][1,3]benzothiazepine StructureJournal of Medicinal Chemistry, 1998
- Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophreniaPsychopharmacology, 1989